Similar Search Results

Does FDI Induce Knowledge Spillovers? Evidence from Indian Pharmaceutical Industry

Jangili, Ramesh; N.R.V.V.M.K., Rajendra Kumar; N., … - 2021

The study examines knowledge spillovers from multinational firms in the Indian pharmaceutical industry. Specifically, we examine whether FDI catalyses diffusion of knowledge transfer from multinational firms’ R&D activities during 2000-01 to 2019-20 and four sub-periods of five years each. The...

Persistent link: https://www.econbiz.de/10013227094

Competition and R&D Financing : Evidence from the Biopharmaceutical Industry

Thakor, Richard T.; Lo, Andrew W. - 2021

The interaction between product market competition, R&D investment, and the financing choices of R&D-intensive firms on the development of innovative products is only partially understood. To motivate empirical hypotheses about this interaction, we develop a model which predicts that as...

Persistent link: https://www.econbiz.de/10013249274

The Impact of R&D Intensity on Firm Performance in South America

Zhang, Xinying - 2022

This study examines the impact of R&D investment on firm performance. This study limits the time frame from 2016 to 2021, and the data sample is the basic data of listed companies active in South America during these six years. Unlike previous studies, these six years included the outbreak and...

Persistent link: https://www.econbiz.de/10014237964

The Dynamics of Research Joint Ventures : A Panel Data Analysis

Duso, Tomaso; Pennings, Enrico; Seldeslachts, Jo - 2008

The aim of this paper is to test the determinants of Research Joint Ventures' (RJVs) group dynamics. We look at entry, exit and turbulence in RJVs that have been set up under the US National Cooperative Research Act, which allows for certain antitrust exemptions in order to stimulate firms to...

Persistent link: https://www.econbiz.de/10014221239

Valuation of Intangible Assets : Estimating Late-Stage Development Cost of Pharmaceutical R&D

Favato, Giampiero; Mills, Roger - 2014

Policy makers need reliable estimates of direct costs of pharmaceutical R&D, in order to contain health-care costs and at the same time maintain a supportive environment for investment in research. This paper evaluates the application of parametric estimating methods to the late stage clinical...

Persistent link: https://www.econbiz.de/10014224317

IP-for-IP or Cash-for-IP? R&D Competition and the Market for Technology

Herbst, Patrick; Jahn, Eric - 2013

This paper argues that firms use 'IP-for-IP' policies such as cross-licensing to strategically restrict transactions in the market for technology. The commitment to limit trade to reciprocal exchange (barter instead of cash transactions) enables firms to alter the allocation of R&D and soften...

Persistent link: https://www.econbiz.de/10014224536

Evaluation and Learning in R&D Investment

Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...

Persistent link: https://www.econbiz.de/10014287391

R&D Tax Credits, Technology Spillovers, and Firms’ Product Convergence

Byun, Seong K.; Oh, Jong-Min; Xia, Han - 2023

Using a difference-in-differences (DiD) setting that leverages the staggered adoption of R&D tax credits across the U.S. states, we show that after a firm receives the tax credits, products of its peers become significantly more similar to the recipient firm. Such product convergence is...

Persistent link: https://www.econbiz.de/10014257686

Industrial and organizational mutations in the medical and pharmaceutical sectors impulsed by open innovation during the pandemic

Adatto, Laurent; Aouinait, Camille; Son Thi Kim Le; … - In: Proceedings of the ENTRENOVA - ENTerprise REsearch … 8 (2022) 1, pp. 421-434

largely based on Open Innovation. For that purpose, exploratory case studies will be shown that exemplify the value of … implementing Open Innovation in the pandemic context. These case studies concern the pharmaceutical firm Pfizer, the biotechnology … systematic analysis of articles, scientific documents, and published reports related to the Open Innovation involvement of these …

Persistent link: https://www.econbiz.de/10014308369

Internal and External R&D : Complements or Substitutes? Evidence from a Dynamic Panel Data Model

Lokshin, Boris; Belderbos, René; Carree, Martin A. - 2006

We examine the impact of internal and external R&D on labor productivity in a 6-year panel of 304 innovating firms. We apply a dynamic linear panel data model that allows for decreasing returns to scale in internal and external R&D with a non-linear approximation of changes in the knowledge...

Persistent link: https://www.econbiz.de/10014054641